<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01603940</url>
  </required_header>
  <id_info>
    <org_study_id>CONTROL STUDY</org_study_id>
    <nct_id>NCT01603940</nct_id>
  </id_info>
  <brief_title>Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine</brief_title>
  <acronym>CONTROL</acronym>
  <official_title>Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Pedro Ernesto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Pedro Ernesto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare losartan and benazepril in diabetic patients whose
      high blood pressure is not controlled by amlodipine and its relationship to statin current
      use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypertension and diabetes mellitus are important risk factors for cardiovascular morbidity
      and mortality. Endothelial dysfunction and vascular rigidity are two pathophysiological
      mechanisms that may explain this relationship. Recent publications showed that both ACEi
      (angiotensin-converting enzyme inhibitor-induced) and ARB (angiotensin receptor blocker) were
      capable of improving vascular stiffness and endothelial function, and that these effects
      occurred despite blood pressure reduction.

      This study main objective is to assess if ARB (losartan) effects are different from ACEi
      (benazepril) in endothelial function in patients with diabetes mellitus type 2 and blood
      pressure not controlled by amlodipine and its relationship to statin current use.

      Secondary analysis of vascular stiffness will be measured by pulse wave velocity and
      augmentation index. Echocardiographic parameters, such as indexes of diastolic function, will
      also be measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>12 weeks</time_frame>
    <description>Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vascular Stiffness</measure>
    <time_frame>12 weeks.</time_frame>
    <description>Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare both groups effects on systolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>Compare both group effects on diastolic blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular Stiffness by Augmentation Index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Hypertension</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benazepril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benazepril</intervention_name>
    <description>Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
    <arm_group_label>Benazepril</arm_group_label>
    <other_name>Lotensin</other_name>
    <other_name>0078-0447-05</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>Cozaar</other_name>
    <other_name>0006-0951-54</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ambulatorial patients with age between 40 and 70 years-old.

          -  Systemic arterial hypertension previously diagnosed and in use of two or less
             anti-hypertensive drugs in the preceding 4 weeks.

          -  Type 2 diabetes mellitus in use of oral medication that were not changed in the
             preceding 4 weeks. Glycated hemoglobin A1c less than 9.0%.

          -  Accepted the consent form.

        Exclusion Criteria:

          -  Office systolic blood pressure equal or more than 180 mmHg, with or without treatment

          -  Office diastolic blood pressure equal or more than 110 mmHg, with or without treatment

          -  Evidences of a secondary cause for hypertension

          -  Glycated hemoglobin A1c &gt; 9.0%

          -  Insulin therapy

          -  Chronic kidney disease stage 4 or 5 or in dialysis

          -  Advanced target organ lesion, obtained by history or additional exams, and defined by:
             previous myocardial infarction, heart failure with ejection fraction less than 40%,
             cerebral vascular accident (ischemic or hemorrhagic), peripheral vascular disease
             (claudication or doppler with obstruction &gt; 50% of vascular lumen), retinopathy with
             visual loss, symptomatic neuropathy.

          -  Cardiac arrhythmias, except for ectopic beats

          -  Any clinical or disabling condition that, in the opinion of the investigators, may
             confound or prejudice study results.

          -  Severe mitral regurgitation.

          -  Women in fertile age without contraceptive methods in use.

          -  Breastfeeding women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wille Oigman, MD, DSc.</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Pedro Ernesto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario F Neves, MD, DSc.</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Pedro Ernesto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronaldo A Gismondi, MD, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Pedro Ernesto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Pedro Ernesto</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>20551030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2012</study_first_submitted>
  <study_first_submitted_qc>May 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2012</study_first_posted>
  <results_first_submitted>August 18, 2015</results_first_submitted>
  <results_first_submitted_qc>October 9, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 11, 2015</results_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Pedro Ernesto</investigator_affiliation>
    <investigator_full_name>Ronaldo Altenburg Odebrecht Curi Gismondi</investigator_full_name>
    <investigator_title>Investigator. Medical Doctor. Master of Sciences.</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Vascular stiffness</keyword>
  <keyword>Endothelial function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Losartan</title>
          <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Benazepril</title>
          <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan</title>
          <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Benazepril</title>
          <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="53" upper_limit="63"/>
                    <measurement group_id="B2" value="57" lower_limit="52" upper_limit="62"/>
                    <measurement group_id="B3" value="57" lower_limit="52" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Function</title>
        <description>Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Benazepril</title>
            <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function</title>
          <description>Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use.</description>
          <units>percentage of maximal vasodilation</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="7.7" upper_limit="13.5"/>
                    <measurement group_id="O2" value="8.8" lower_limit="6.9" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Stiffness</title>
        <description>Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril).</description>
        <time_frame>12 weeks.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Benazepril</title>
            <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Stiffness</title>
          <description>Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril).</description>
          <units>m/s</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" lower_limit="7" upper_limit="9.7"/>
                    <measurement group_id="O2" value="8.5" lower_limit="7.8" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Compare both groups effects on systolic blood pressure.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Benazepril</title>
            <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Compare both groups effects on systolic blood pressure.</description>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" lower_limit="127" upper_limit="143"/>
                    <measurement group_id="O2" value="139" lower_limit="130" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.618</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Compare both group effects on diastolic blood pressure.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Benazepril</title>
            <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Compare both group effects on diastolic blood pressure.</description>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="69" upper_limit="84"/>
                    <measurement group_id="O2" value="82" lower_limit="74" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vascular Stiffness by Augmentation Index</title>
        <description>Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Benazepril</title>
            <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Vascular Stiffness by Augmentation Index</title>
          <description>Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups.</description>
          <units>percentage of augmentation pressure</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28" lower_limit="21" upper_limit="37"/>
                    <measurement group_id="O2" value="35" lower_limit="26" upper_limit="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>This group will receive 100 mg of losartan per day. Amlodipine will be maintained.
Losartan: Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Benazepril</title>
          <description>This group will receive 20 mg of benazepril per day. Amlodipine will be maintained.
Benazepril: Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>edema</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <description>Not severe edema in losartan group.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title vocab="cough">Cough</sub_title>
                <description>Cough due to benazepril (ACEi: angiotensin-converting enzyme inhibitor-induced)</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronaldo Altenburg Gismondi, MD, PhD</name_or_title>
      <organization>Hospital Universitario Pedro Ernesto (UERJ)</organization>
      <phone>+5521996092383</phone>
      <email>ronaldogismondi@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

